SUMMARY Double-stranded DNA immune complexes (DNA-ICs) were assayed by millipore filtration and deoxyribonuclease digestion in 40 patients with both active and inactive systemic lupus erythematosus (SLE). The assay is superior to the double-stranded DNA antibody (ds ADA) as an indicator of active disease, and, when combined with the total haemolytic complement (CH5.) and ds ADA levels it increases the prediction of the relative risk of active disease. A good correlation between actual levels of DNA-ICs and the degree of activity was also shown. We conclude that measurement of DNA-ICs is of value as an additional monitor in the assessment of activity in SLE. 
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A number of laboratory tests are available for the diagnosis of SLE and for the assessment of activity.'`8
The most useful diagnostic test is the demonstration of increased concentrations of ds ADA, because with rare exceptions it is found exclusively in SLE. A normal ADA level, however, does not exclude the diagnosis. Depression of CH50, C3, C4, and elevated ADA levels are highly suggestive, but not invariable, indicators of active lupus. The observation of abnormal values for the above in the absence of apparent clinical activity may be due to an inabiity to recognise minor grades of activity at the bedside. Methods exist for the detection of antigen nonspecific immune complexes,9'2-but there are few assays for detecting complexes to specific antigens. [22] [23] [24] A new technique for the detection of DNA-ICs based on the principle of millipore filtration and deoxyribonuclease digestion has been shown to be highly specific for SLE."5 This study was designed to evaluate the latter in the following terms: (1) as a monitor of disease activity; (2) whether the presence of DNA-ICs in the circulation in the absence of clinical activity heralds the onset of active disease; (3) the relationship between actual levels of DNA-ICs and the severity of the acute episode.
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Results
Of the 40 patients 15 remained clinically inactive during the 30-month period of study, while in the remaining 25 patients 44 acute flares were recorded. In the latter group 13 were on corticosteroid and/or immunosuppressive therapy at the time of the flare. The dosage was increased in 9 patients to control symptoms, while corticosteroid therapy was begun in 9.
The clinical manifestations of the 25 patients who developed active disease and the relationship to circulating DNA-IC are shown in Table 2 . Arthritis and skin involvement accounted for the majority of active episodes both when they occurred alone (12 and 11 episodes respectively) or when they occurred as part of a more general flare with other organ involvement (21 and 20 episodes respectively). One hundred and twenty nine single DNA-IC assays were performed, 76 during active and 53 during quiescent phases of the disease. In 2 patients several IC measurements were made over a 24-hour period during active disease, and the mean of these levels was taken to represent the IC level for the particular episode. ADA levels were measured in 188, and CH50 in 176 samples from the patients during the same period of study. The results obtained are shown in Table 3 . only in patients with life-threatening disease with the exception of one patient with a major flare, in whom the level was 7-40 units/ml. An analysis of DNA-IC levels in the different grades of disease activity shows that, while the difference between DNA-IC levels in inactive disease compared to minor activity was not significant, the mean levels in the 3 groups, (1) inactive plus minor, (2) major, and (3) life-threatening activity, were significantly different at the 0 02 significance level. Allowance was made in the analysis for the small number of patients with life-threatening disease.
Eleven patients with raised DNA-ICs and clinically inactive disease were carefully observed for the subsequent development of active disease. The outcome is shown in Table 4 . Three patients did not develop any evidence of active disease over a 30-month period of observation while 6 (55 %) had minor and 2 (18 %) had major flares. The onset of the active episodes ranged from 1 to 9 months. Of the 11 -patients 6 (55%) had unequivocal renal lupus histologically, and 2 (18%) patients had had granular casts on a few occasions in the past. The remaining 3 patients at no stage showed any evidence of renal involvement. 
